Business Trends– category –
-
Cellistic Expands iPSC Therapy Manufacturing with New GMP Platforms for Immuno-Oncology and Regenerative Medicine
Cellistic Press Release (via PharmaTimes) Belgium Overview Cellistic has introduced three new GMP manufacturing platforms—Echo-T, Echo-Cardio, and Echo-Endothelial—significantly expanding its capabilities for iPSC-derived cell therapies.... -
AI-Guided 3D Bioreactors Revolutionize iPSC Manufacturing: Scaling Up and Cutting Costs for Accelerated Commercialization
Wiley Analytical Science USA Overview AI-guided 3D bioreactor technology is revolutionizing iPSC manufacturing, enabling reliable, efficient, and scalable production of pluripotent stem cells (PSCs). This innovative platform facilitates ... -
Bristol Myers Squibb Terminates $380M CAR-T Manufacturing Partnership with Cellares Due to Production Failures for Breyanzi
PharmaLive USA Overview Bristol Myers Squibb (BMS) has ended its $380 million partnership with Cellares, citing Cellares' Cell Shuttle system's failure to meet commercial production requirements for BMS's CAR T-cell immunotherapy, Breyan... -
Precision BioSciences Initiates Phase 1/2 FUNCTION-DMD Clinical Trial for PBGENE-DMD Gene Therapy: Applicable to 60% of DMD Patients, Initial Safety Data Expected by Year-End
Precision BioSciences, Inc. (Press Release) USA Overview Precision BioSciences announced the initiation of patient dosing in its Phase 1/2 FUNCTION-DMD clinical trial for PBGENE-DMD, an in vivo gene editing therapy for Duchenne muscular ... -
CRISPR Therapeutics Diversifies Pipeline into In Vivo Gene Editing and Off-the-Shelf CAR-T Cell Therapies, Leveraging Casgevy Commercialization Experience
Venture Atlas USA Overview CRISPR Therapeutics is strategically diversifying its pipeline, leveraging its commercialization experience with Casgevy, into in vivo gene editing programs (CTX310, CTX320, CTX340, CTX460) and allogeneic off-t... -
USC Initiates Phase 1 REPLACE™ Clinical Trial for Parkinson’s with Autologous iPSC-Derived Dopaminergic Neurons (RNDP-001), Aiming to Restore Motor Function
Dr. Marie Laguna's Blog USA Overview Keck Medicine of USC commenced a Phase 1 REPLACE™ clinical trial in 2026 for Parkinson's disease, utilizing autologous iPSC-derived dopaminergic neural cells (RNDP-001). This innovative therapy aims t... -
SK Group Inks $795M Deal to Propel Biohaven’s Epilepsy Therapy Toward FDA Approval
Fierce Biotech USA Overview SK Group has signed a $795 million strategic agreement to accelerate Biohaven's epilepsy drug candidate towards U.S. FDA approval. This significant partnership highlights the importance of financing and develo... -
Eli Lilly Builds Pharmaceutical Industry’s Largest AI Factory with NVIDIA Blackwell DGX SuperPODs, Secures Multi-Billion Dollar Deals with Insilico Medicine and Isomorphic Labs
GlobeNewswire USA Overview In Q2 2026, as AI technology investment accelerated across industries, Eli Lilly announced the construction of the pharmaceutical sector's largest AI factory, powered by NVIDIA Blackwell-based DGX SuperPODs. Co... -
AI M&A Surges to One-Third of All Deals in August 2026, Reshaping Software Industry; Nvidia Secures $6B Poolside Licensing Deal
AIFOD USA Overview AI-related mergers and acquisitions accounted for 140 of 457 total M&A deals in August 2026, signaling a profound restructuring of the software industry. Key transactions include Nvidia's $6 billion non-exclusive l... -
Quantinuum and Quanta Computer Forge Joint Development Agreement for Industrialization of Fault-Tolerant Trapped-Ion Quantum Hardware Manufacturing
Quantinuum USA Overview Quantinuum, a trapped-ion quantum computing developer, and Quanta Computer, a Fortune Global 500 electronics manufacturer, have signed a joint development agreement to industrialize hardware infrastructure, system...
